Dr. Wayne Freese
CEO/President, Chairman of the Board
Dr. Freese has practiced veterinary medicine for more than 40 years in Southwest Minnesota. He co-founded both Oxford Laboratories (now owned by Merck) and Newport Laboratories (now owned by Merial).
Dr. Freese has served as a consulting veterinarian in Europe, Asia, Mexico, and Canada. He is a past President of the American Association of Swine Practitioners and the Interstate Veterinary Medical Association. He has served as a bank director and held positions on several economic planning committees in Southwest Minnesota. In his spare time, Dr. Freese enjoys fishing and hunting.
- BS Animal Science, DVM Veterinary Medicine – Iowa State University
- MS Swine Production Medicine – University of Minnesota
Jon Mahlberg
Chief Operating Officer
Jon has over 20 years of experience in animal health biologics. Prior to Cambridge, he worked at Newport Laboratories in Diagnostics, Research and Development, Quality Systems, and Manufacturing. He has held various management positions in Production, R&D, Technical Transfer, and Regulatory Affairs. Jon was the project leader for the first and only USDA-licensed modified live Haemophilus parasuis vaccine. His interests in lean manufacturing, process improvement, and KPI assessment tools will help to lead Cambridge Technologies’ manufacturing to a high level of excellence and customer satisfaction.
Dr. Randy Simonson
Chief Strategy Officer
Dr. Simonson began his career as a scientist for Salsbury Laboratories, becoming the Manager of Biological Development. He served as Manager of Biologic Development for Solvay before moving to Oxford Laboratories, first as Team Manager, licensing the original swine biologics line for the company and later becoming Vice President of Research and Development. After Oxford was purchased by The Upjohn Company, he became the Director of Biological Development Worldwide. Following the purchase of Upjohn by Bayer, he advanced to Director of Biologics Project Management Worldwide.
Dr. Simonson comes to Cambridge Technologies from Newport Laboratories where he was the Chief Operating Officer and later President. He has authored numerous publications and patents regarding biologic research and product applications and is often requested as a speaker and presenter at both domestic and international technical meetings.
- BS., California Polytechnic University
- Ph.D., Veterinary Microbiology, University of Minnesota
- 2001 Recipient, Distinguished Research Award, University of Minnesota
- In 2018, Dr. Simonson was elected to serve on the University of Minnesota Board of Regents